Approach

Summary

Licensing status

Publication and contact information

Drug platforms

Direct in vivo reprogramming of pancreatic acinar cells into d-like and a-like pancreatic cells

Direct in vivo reprogramming of pancreatic acinar cells into d- and a-like pancreatic islet cells could be used to generate pancreatic islets to treat diseases such as type 1 diabetes. In mice, intrapancreatic injection of an adenoviral vector encoding neurogenin 3 (Ngn3) converted acinar cells into d-like pancreatic islet cells. In mice, intrapancreatic injection of adenoviral vectors encoding Ngn3 and v-maf musculoaponeurotic fibrosarcoma oncogene homolog A (Mafa; Ripe3b1) converted acinar cells into a-like pancreatic islet cells. Next steps include creating islets that contain the full repertoire of acinar tissue-derived endocrine cells.

SciBX 7(19); doi:10.1038/scibx.2014.570
Published online May 15, 2014

Patented; available for licensing

Li, W. et al. eLife; published online April 8, 2014;
doi:10.7554/eLife.01846
Contact: Qiao Zhou, Harvard University, Cambridge, Mass.
e-mail:

qiao_zhou@harvard.edu